The following is an interview with Dr Eric Jonasch, Professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, at the MD Anderson Cancer Center of The University of Texas in Houston, USA, where he is also Co-Chair of the Renal Cancer Program.

Dr Jonasch discusses the data on the efficacy of new first-line treatments for metastatic renal cell carcinoma (mRCC), and the use of cabozantinib, nivolumab, and ipilimuab, as well as standard treatments, such as sunitinib and pazopanib in the first-line setting.

See the video interview on Practise Update here